Pharmaron

Pharmaron

Pharmaceutical Manufacturing

Premier life science service provider

About us

Pharmaron (Stock Code: 300759.SZ/3759.HK) is a premier service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of research, development and manufacturing service capabilities throughout the entire drug discovery, preclinical and clinical development process across multiple therapeutic modalities, including small molecules, biologics and CGT products. With over 20,000 employees and operations in China, the U.S., and the U.K., Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China. Services: * Synthetic, medicinal and analytical chemistry services * Biology services * DMPK services * Pharmacology services * Drug safety assessment services * Radiochemistry and isotopically labelled metabolism services * Chemical & pharmaceutical development services * Clinical development services www.pharmaron.com CRO - Contract Research Organization & CDMO - Contract Development Manufacturing Organization Library Synthesis CADD Bioorganic Chemistry Discovery Process Chemistry Radiolabelled Chemical Synthesis ChemInformatics in vitro Biology in vitro Screening Structural Biology in vivo Pharmacology Animal Disease Models ex vivo Pharmacology Biomarkers in vitro ADME in vivo PK PKPD QA Regulatory Affairs Discovery Biologics Process Chemistry API Manufacturing Material Science Formulation Development Drug Product Manufacturing Toxicology Safety Pharmacology Genetic Toxicology DART Pathology Immunotoxicity Bioanalytical 14C / Carbon-14 Radiosynthesis 3H / Tritium Radiosynthesis QWBA mARG Clinical AME Mass Balance Metabolite Profiling Microdosing Phase 0 Absolute Bioavailability DDI First-in-Human (FIH) Thorough QT(TQT) Ethnobridging

Industry
Pharmaceutical Manufacturing
Company size
10,001+ employees
Headquarters
Beijing
Type
Privately Held
Specialties
Chemistry, Biology, DMPK, Pharmacology, Chemical Development, Preclinical, Toxicology, Safety Pharmacology, Discovery, Lead Optimization, Process Development, Assay Development, ADME, Formulation, clinical pharmacology, analytical sciences, radiolabelled chemistry, accelerator mass spectrometry, radiolabelled compounds, API manufacturing, radiosynthesis, Biologics, and CTG Products

Locations

Employees at Pharmaron

Updates

  • View organization page for Pharmaron, graphic

    38,536 followers

    Just 2 weeks to go! Don’t miss Pharmaron’s Integrated Drug Discovery webinar - 𝐌𝐚𝐜𝐫𝐨𝐜𝐲𝐜𝐥𝐞𝐬: 𝐀𝐧 𝐈𝐧𝐜𝐫𝐞𝐚𝐬𝐢𝐧𝐠𝐥𝐲 𝐏𝐨𝐩𝐮𝐥𝐚𝐫 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐲 𝐢𝐧 𝐃𝐫𝐮𝐠 𝐃𝐞𝐬𝐢𝐠𝐧 ➡️ 𝐖𝐡𝐞𝐧? December 5th at 8am PT / 11am ET / 4pm GMT In this session, experts Mike Waring (Newcastle University) and Sebastien Campos (Pharmaron) will explore the growing role of macrocycles in drug design, highlighting their unique advantages, challenges, and practical applications through case studies. 💡 Curious about what’s in store? 𝐖𝐚𝐭𝐜𝐡 this quick overview from Kevin Foote, VP of Drug Discovery Services Europe, for a sneak peek into the webinar! ➡️ Register now: https://lnkd.in/gXZ3Cdiq #Pharmaron #DrugDiscovery #Macrocycles #Webinar #DrugDesign

  • View organization page for Pharmaron, graphic

    38,536 followers

    Save the Date! Join us for an in-person workshop, Powder X-Ray Diffraction: From a Pharmaceutical Perspective, hosted by Pharmaron and Bruker. Explore cutting-edge developments in pharmaceutical analysis and connect with industry experts!   🗓️ When: 3rd - 5th February 2025 📍 Where: Pharmaron Hoddesdon, UK 👉 Register here: https://lnkd.in/dXbqfpQW   Don’t miss this opportunity to elevate your knowledge and network with peers in the field! #PharmaceuticalInnovation #SaveTheDate #Pharmaron

    • No alternative text description for this image
  • View organization page for Pharmaron, graphic

    38,536 followers

    This Thanksgiving, we’re reflecting on the power of collaboration and our progress with our partners to advance healthcare and scientific innovation. At Pharmaron, we are grateful for the dedication of scientists, researchers, and healthcare professionals working tirelessly to bring life-changing solutions to patients and families. As we celebrate today, we extend our deepest thanks to everyone who shares our commitment to a healthier future. Together, we’re building the foundations for meaningful discoveries and improvements in patient care. We wish everyone a safe and happy Thanksgiving. #Thanksgiving #Pharmaron #LifeSciences #HealthInnovation #Gratitude

    • Wooden board with "Happy Thanksgiving" text surrounded by autumn leaves, acorns, and seasonal decorations.
  • View organization page for Pharmaron, graphic

    38,536 followers

    That's a wrap on BOS Manchester 2024!  We’re thrilled by the success of the event, filled with fantastic networking opportunities, insightful talks, and a truly welcoming atmosphere. It was a pleasure connecting with so many brilliant minds in the field. Until next time, learn more about Pharmaron’s services by visiting our website: https://lnkd.in/ewVsK4aU. #Pharmaron #BOSManchester #Networking #LifeSciences #PharmaInnovation

  • View organization page for Pharmaron, graphic

    38,536 followers

    𝐉𝐨𝐢𝐧 𝐔𝐬 𝐟𝐨𝐫 𝐎𝐮𝐫 𝐔𝐩𝐜𝐨𝐦𝐢𝐧𝐠 𝐃𝐌𝐏𝐊 𝐖𝐞𝐛𝐢𝐧𝐚𝐫! Brain Penetration Concepts, Challenges and Mitigation Strategies for Biologics and Novel Constructs. How Low Can You Go? 🗓 𝐃𝐚𝐭𝐞: December 11th ⏰ 𝐓𝐢𝐦𝐞: 8am PT/11am ET/ 4pm GMT We’re excited to feature three leading experts in the field who will share their insights into brain penetration strategies for biologics: 🔹 James Yates: Scientific Director at GSK and leads the nonclinical PKPD modelling team in DMPK, Preclinical Sciencs. He has a background in mathematics and engineering (University of Warwick, UK) and has 20  years’ experience in drug discovery and development, particularly in oncology. He has published 90 papers on translational PKPD. He has a particular interest in the application of mathematical modelling for translation from nonclinical to patients and between patient populations.  🔹 David Fairman: Dave is currently CPMS Translational head at GSK and is accountable for oversight and guidance of early phase clinical pharmacology studies. His background is in translational pharmacology with a specialisation in biologics including TMDD modelling and assay selection best practise. 🔹 Scott Summerfield: Senior Director, Pharmaceutical Metabolism at Pharmaron Don’t miss the opportunity to deepen your understanding of this critical area in drug development! ➡️ 𝐑𝐞𝐠𝐢𝐬𝐭𝐞𝐫 𝐧𝐨𝐰: https://lnkd.in/eRcpeE79 #DMPK #BrainPenetration #Pharmaron #Webinar #DrugDevelopment

    • No alternative text description for this image
  • View organization page for Pharmaron, graphic

    38,536 followers

    Looking to optimise your drug development strategy? Don’t miss Sanjeev Sood and Simon Taylor from Pharmaron at BOS Manchester 2024! Their talk, "Formulation and PK Integration: A Fast-Track to Drug Development Success," will provide valuable insights for accelerating timelines and ensuring success. 🗓️ When: Tuesday, 26th November, 3 PM 📍 Where: BOS Manchester Connect with the Pharmaron team at Booth 11 to learn more about how they can support your R&D goals! #DrugDevelopment #Pharmaron #BOSManchester2024

  • View organization page for Pharmaron, graphic

    38,536 followers

    Join Pharmaron at Phacilitate, Advanced Therapies Week in Dallas, January 20–23, 2025! Visit us at Booth #675 to learn more about our CGT CRO and CDMO capabilities. Our team is here to discuss how we can support your advanced therapy program with expertise spanning discovery to commercialization, including analytical testing, safety studies, and scalable manufacturing solutions. Schedule a meeting with our experts to explore how we can help you accelerate your pathway to regulatory approval and commercialization. Schedule a meeting at your convenience: https://lnkd.in/eAYEURPb Let’s advance the future of cell and gene therapy together. #Pharmaron #AdvancedTherapiesWeek #Phacilitate #CellAndGeneTherapy #CGT #ATW25

    • This is an event promo poster for an upcoming conference that the company is exhibiting at. It is a mostly white poster company and event logo in the top left and right corner, as well as an image of a skyline in the bottom right corner. There is a long green button that offers to schedule a meeting.
  • View organization page for Pharmaron, graphic

    38,536 followers

    Thank you to everyone who joined our webinar on Pharmaron’s AAV Production Platform! We had an engaging session discussing how our innovative approach can streamline the journey of AAV products to BLA/MAA submission. Key highlights included: > The therapeutic potential of AAV > Essential platform considerations > Strategies to overcome production challenges If you missed it, don’t worry! You can access the on-demand recording here: https://lnkd.in/dkeTmB6K #CGT #Pharmaron #LifeSciences #CDMO #IND

    • This is a blue post-webinar promotional poster offering an On-demand version of the webinar that just took place. The Pharmaron company logo is in the top left corner and the title is centered on the page.
  • View organization page for Pharmaron, graphic

    38,536 followers

    Join us for our next 𝐯𝐢𝐫𝐭𝐮𝐚𝐥 𝐜𝐡𝐞𝐦𝐢𝐬𝐭𝐫𝐲 𝐥𝐞𝐜𝐭𝐮𝐫𝐞 on Thursday, November 28, 2024, at 4:00 pm (China Standard Time).     𝐍𝐞𝐰 𝐀𝐩𝐩𝐫𝐨𝐚𝐜𝐡𝐞𝐬 𝐭𝐨 𝐇𝐢𝐭 𝐆𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐔𝐬𝐢𝐧𝐠 𝐅𝐫𝐚𝐠𝐦𝐞𝐧𝐭𝐬 𝐚𝐧𝐝 𝐃𝐍𝐀-𝐞𝐧𝐜𝐨𝐝𝐞𝐝 𝐋𝐢𝐛𝐫𝐚𝐫𝐢𝐞𝐬  Prof. Michael Waring  Chemistry, School of Natural and Environmental Sciences,  Newcastle University, UK    𝐑𝐞𝐠𝐢𝐬𝐭𝐞𝐫 for the webinar: https://lnkd.in/gy3D-NQA In this lecture, Prof. Mike Waring will discuss his approach to DEL synthesis using micelle-mediated chemical reactions that leads to much improved efficiency allowing the synthesis of higher fidelity DELs. Prof. Mike Waring has employed this technology to develop a range of library forming reactions, including Suzuki, amide, Buchwald, Heck and Sonogashira couplings as well as reductive aminations and hydrogenation. Prof. Waring has employed this chemistry in the synthesis of screening libraries but also to poised DELs for fragment expansion, termed NUDELs. This approach has been demonstrated with the development of a potent and highly ligand efficient lead for BRD4 from a weak fragment whose affinity arises from synergistic protein-ligand interactions that could not have been discovered by other means. #VirtualLecture #Pharmaron #Hitgeneration #DNA #DEL

    • No alternative text description for this image

Affiliated pages

Similar pages

Browse jobs

Funding

Pharmaron 4 total rounds

Last Round

Post IPO equity

US$ 587.8M

See more info on crunchbase